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Objectives: To estimate the cost-effectiveness of nab-paclitaxel+gemcitabine (Npg) 
versus gemcitabine (Gem) alone for the first-line treatment of metastatic pancreatic 
cancer in Greece from a National Health System perspective MethOds: A Markov 
model was developed, included several stages such as: “pre-progression on first-
line treatment”, “pre-progression off first-line treatment”, “post progression”, “four 
weeks to death” and “death”. Data from the MPACT trial were used to estimate overall 
survival (Life-Years- (LYs)) and adverse events. The prices of drugs used in the model 
are publicly available for all hospitals in Greece. Cost assigned in each health state 
reflected: drugs, adverse events, monitoring, administration and palliative care. Utility 
values were obtained from the international literature to estimate Quality-Adjusted-
Life-Years (QALYs). Costs and health gains were discounted at 3.5% per annum. A 
probabilistic sensitivity analysis was also conducted to construct confidence inter-
vals (CI). Results: The mean number of QALYs was 0.71 (95%CI: 0.66–0.78) and 0.56 
(95%CI: 0.52–0.60) for Npg and Gem, respectively, giving an incremental gain of 0.15 
(95%CI: 0.08-0.25) QALYs in favour of Npg. The mean cost of therapy per patient was 
estimated at € 15,628 (95%CI: € 14,377- € 17,027) and € 8,284 (95%CI: € 7,455-€ 9,112) for 
Npg and Gem, respectively. The incremental cost per LY gained with Npg was esti-
mated at € 37,007 and the incremental cost per QALY gained at € 47,120. The probability 
for Npg to be cost-effective at a threshold three times the per capita income (€ 60,000 
per QALY) was 82%. cOnclusiOns: The severity of pancreatic cancer, in combination 
with the limited number of effective treatments, results in a high level of unmet need. 
If the societal willingness-to-pay threshold for an additional QALY is relatively higher 
for patients with short life expectancy or for diseases with a relatively higher burden, 
the combination of nab-paclitaxel+gemcitabine could be considered a cost-effective 
choice compared with gemcitabine alone in Greece.
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Objectives: To compare the cost-effectiveness of panitumumab plus mFOLFOX6 
(oxaliplatin, 5-fluorouracil and leucovorin) versus bevacizumab plus mFOLFOX6 
as first-line treatment for patients with wild-type RASmetastatic colorectal cancer 
(mCRC). MethOds: Using a French health collective perspective, a lifetime Markov 
model was constructed, with health states related to first-line therapy (progression-
free), disease progression with/without subsequent active treatment, resection of 
metastases, disease-free after successful resection, and death. Transitions to disease 
progression and death were estimated using parametric survival analyses of patient-
level progression-free (PFS) and overall (OS) survival from the only head-to-head clini-
cal trial of panitumumab versus bevacizumab in mCRC (PEAK). Additional data from 
PEAK informed the amount of each drug consumed, duration of therapy, subsequent 
therapy use, and toxicities related to mCRC treatment. Literature and French public 
data sources were used to estimate unit costs associated with treatment, duration 
of subsequent active therapies, and survival post-resection. Patient-level data from 
panitumumab trials in the first-, second-, and third-line settings were used to deter-
mine utility weights. One-way and probabilistic sensitivity analyses were performed. 
Scenario analyses examined modelling of PFS and OS using observational survival 
data and PEAK hazard ratios. Results: Based on the better efficacy outcomes for 
patients with wild-type RASmCRC who received panitumumab plus mFOLFOX6 ver-
sus bevacizumab plus mFOLFOX6 in PEAK, the incremental cost per life-year gained 
was estimated to be € 26,918, and the incremental cost per quality-adjusted life year 
(QALY) gained was estimated to be € 36,577. Sensitivity and scenario analyses indi-
cate the model is robust to alternative parameters and assumptions. cOnclusiOns: 
Panitumumab plus mFOLFOX6 can be considered cost-effective in first-line treatment 
of patients with wild-type RAS mCRC.
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Objectives: To assess the cost-utility of pazopanib vs. sunitinib as first-line treat-
ment of mRCC from the Spanish National Healthcare perspective. MethOds: A 
published partitioned-survival analysis model was used to estimate the incremental 
cost-utility ratio (ICUR) of pazopanib vs. sunitinib. Progression free survival (PFS) and 
overall survival (OS) data from COMPARZ (NCT00720941), a non-inferiority head to 
head phase III-trial of sunitinib vs. pazopanib, were used to generate survival func-
tions up to overall time horizon. Patients can be in one of three mutually exclusive 
health states over time: alive and no progression, alive with progression and dead. 
Utilities values were obtained from PISCES trial (NCT01064310) and adjusted tak-
ing into account the different treatment schedules (sunitinib-cycles: 4 weeks-on 
plus2 weeks-off; pazopanib 800 mg/day). Health resource utilization was collected 
using individual patient data from COMPARZ trial and their corresponding unit 
costs were retrieved from published Spanish tariffs. Base-case analysis considered: 
ing to develop a targeted contrast agent that specifically detects adenomas at 
increased risk of progressing to CRC. This might even further raise the potential 
of MR colonography. We explored the potential of conventional and targeted MR 
colonography in terms of (cost-) effectiveness using the ASCCA model. MethOds: 
Thirteen screening strategies were evaluated, differing in primary screening 
instrument and number of screening rounds. The strategies under consideration 
were conventional and targeted MR colonography, colonoscopy and CT colonog-
raphy with two, three and four screening rounds at a ten year screening interval. 
Furthermore, eleven rounds of biennial faecal immunochemical test (FIT) screen-
ing were considered. Each strategy was evaluated assuming realistic and perfect 
participation rates. Incremental costs and effects were estimated from a societal 
perspective. Results: All screening strategies were cost-effective compared to 
no screening. For conventional MR colonography, the ICER ranged between € 1,271/
LYG to € 3,003/LYG for two to four screening rounds at 34% participation per round. 
For 62% and 100% participation, the ICER ranged from respectively € 1,576/LYG to 
€ 3,777/LYG and € 1,971/LYG to € 4,577/LYG. However, conventional MR colonography 
screening was more expensive than other screening strategies at comparable 
LYG, for all participation rates. Targeted MR colonography was only slightly more 
effective than conventional MR colonography but considerably more costly, even 
under the most favourable assumptions regarding test characteristics and costs 
per test. cOnclusiOns: This is the first study to evaluate the cost-effectiveness 
of MR colonography screening for CRC. Although conventional and targeted MR 
colonography are cost-effective compared to no screening, at present they cannot 
compete with more established screening tests because of the high costs per test.
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Objectives: To assess the cost-effectiveness of Abiraterone Acetate plus 
Prednisone (A-P) compared with Cabazitaxel plus Prednisone (C-P) in Panama, 
in patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) that 
have failed to chemotherapy with Docetaxel. MethOds: A three-health state 
cohort simulation Markov Model (progression-free, post-progression and death) 
was developed based on overall and progression free survival data. The time frame 
was 10 years. The perspective was that of the Public System of Health of Panama. 
The health outcomes of interest were Quality Adjusted Life Years (QALYs) and Life 
Years (LYs). Efficacy data was taken from clinical trials (COU-AA-301 for A-P and 
TROPIC for C-P). Utilities for health states and negative utilities for adverse events 
were estimated based on quality of life endpoints of the COU-AA-301 trial. The 
base year was 2012. All costs are presented in United States Dollars (USD). Costs 
and outcomes were discounted at 5%. Probabilistic sensitivity (PSA) analysis was 
performed to evaluate uncertainty surrounding the parameters. Results: A-P 
resulted in 0.79 QALYs and 1.35 LYs, per patient, respectively. C-P resulted in 0.71 
QALYs and 1.28 LYs, per patient, respectively. Mean total costs per patient were: 
USD 76.179 for A-P and USD 86.286 for C-P. The results of the probabilistic sensitiv-
ity analysis showed that, when compared with C-Z, A-P was found dominant (asso-
ciated with reduced costs and increased QALYs) in the majority of the iterations. 
A-P had a 73% probability of being cost effective, independent of the willingness 
to pay, when compared to C-P. When the willingness to pay increases, A-P is more 
likely to become cost effective. cOnclusiOns: A-P can be considered dominant 
(cost-saving), when compared with C-P, in patients with Metastatic Castration-
Resistant Prostate Cancer that have failed to chemotherapy with Docetaxel, from 
the perspective of the Public System of Health of Panama.
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Objectives: This study evaluated the cost-effectiveness of everolimus plus exemes-
tane (EVE+EXE) versus exemestane (EXE) and fulvestrant (FUL) in the treatment of 
postmenopausal women with ER+ HER2- metastatic breast cancer in the United 
Kingdom (UK) from a societal perspective. MethOds: A partitioned survival model 
was developed to compare treatment with EVE+EXE versus EXE and FUL over a 
10-year time horizon. Progression-free survival and overall survival for EVE+EXE 
and EXE were estimated from the BOLERO-2 trial. Log-logistics functions were used 
to extrapolate trial data beyond the follow-up period. In the absence of head-to-
head evidence vs. FUL an indirect treatment comparison was conducted using a 
Bayesian fixed effect model. Background health state and terminal care resource 
use were derived from NICE Clinical Guideline 81. Drug costs were taken from the 
British National Formulary. Productivity loss, defined as working days lost due to 
disease, was included in the analysis. Utilities from published sources were com-
bined with trial data to calculate quality-adjusted life years (QALYs) for the model 
health state. Results: EVE+EXE led to an incremental gain in life years of 0.20 vs. 
EXE and 0.19 vs. FUL. The incremental QALY gain was 0.31 vs. EXE and 0.27 vs. FUL. 
The cost of lost productivity was £66,163 in the EVE+EXE compared to £75,067 in the 
EXE arm and £73,434 in the FUL arm. The incremental cost per QALY was £27,644 
vs. EXE and £14,030 vs. FUL. Probabilistic sensitivity analysis demonstrated that, at 
a threshold of £30,000 per QALY gained, EVE+EXE had a 51.6% likelihood of being 
cost-effective vs. EXE and 59.0% vs. FUL. cOnclusiOns: Patients receiving EVE+EXE 
experienced an improvement in survival which translated into health gains in terms 
of both LYs and QALYs. EVE+EXE was associated with savings in productivity costs 
compared to both EXE and FUL.
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Objectives: To conduct a cost-effectiveness analysis of panitumumab plus mFOL-
FOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment (FLT) of metastatic 
colorectal cancer (mCRC) patients with wild-type RASin the Greek health care set-
ting. MethOds: An existing Markov model consisting of seven health states was 
adapted from the public third-party-payer perspective. Both efficacy and safety data 
considered in the model were extracted from the PEAK trial and other published 
studies. Utility values were also extracted from the literature. Direct medical costs 
consisting of drug-acquisition costs for FLT, administration costs, subsequent ther-
apy costs and other medical costs were incorporated into the model and reflect the 
year 2014. Primary outcomes were patient survival (life-years), quality-adjusted life 
years (QALYs) and the incremental cost-effectiveness ratio (ICER) per QALY gained. 
Probabilistic sensitivity analysis (PSA) was conducted to account for uncertainty 
and variation in the parameters of the model. Results: The analysis showed that 
panitumumab plus mFOLFOX6 produced greater discounted survival and quality 
adjusted survival by 0.87 LYs and 0.65 QALY benefit in relation to bevacizumab plus 
mFOLFOX6. The total lifetime cost was € 75,200 and € 52,736 for panitumumab and 
bevacizumab plus mFOLFOX6, respectively. This difference was mainly attributed 
to the higher acquisition cost of panitumumab compared to bevacizumab during 
the pre-progression health state (€ 32,223 and € 14,730 respectively). Incremental 
analysis showed that panitumumab plus mFOLFOX6 was more effective and more 
costly than bevacizumab plus mFOLFOX6 resulting in an ICER equal to € 34,644 
per QALY gained. PSA revealed that the probability of panitumumab plus mFOL-
FOX6 being cost-effective over bevacizumab plus mFOLFOX6 was 81.5% at the pre-
determined threshold of € 51,000 per QALY gained (3 times the GDP per capita of 
Greece). cOnclusiOns: The results suggest that panitumumab plus mFOLFOX6 
may be a cost-effective alternative relative to bevacizumab plus mFOLFOX6 as FLT 
of mCRC patients with wild-type RASin Greece.
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Objectives: To conduct an economic evaluation comparing pegfilgrastim with 
filgrastim or lenograstim used either in an 11-day regimen or in a 6-day regimen for 
the prophylaxis of febrile neutropenia (FN) in breast cancer patients, in the Greek 
health care setting. MethOds: A cost-effectiveness model was locally adapted from 
the public third-party-payer perspective. Efficacy and utility values extracted from 
published studies were considered in the model. The analysis was conducted for a 
6-cycle horizon, to reflect the common clinical practice in Greece. Drug acquisition 
costs, administration costs and FN management reimbursed costs were considered 
(in € 2014). The outcomes of the model were the incremental cost per additional FN 
event avoided and per QALY gained (ICER) of pegfilgrastim to its comparators. The 
ICERs were evaluated at the predetermined willingness-to-pay threshold of € 34,000/
QALY gained. Results: The incremental cost per additional FN event avoided with 
pegfilgrastim ranged between € 11,015 and € 27,079 compared to 11-day regimens of 
originator and a biosimilar filgrastim respectively, while pegfilgrastim was found 
to be dominant compared to the 11-day regimen of lenograstim. Comparing peg-
filgrastim with the 6-day regimen of filgrastim and lenograstim, it was found that 
the ICER per additional FN event avoided ranged between € 9,538 and € 15,207 in case 
of lenograstim and biosimilar filgrastim respectively. Similarly, cost-utility analysis 
revealed that pegfilgrastim was cost-effective over 11-day and 6-day regimens of 
originator filgrastim with ICERs of € 11,065 and € 19,942/QALY gained, respectively. 
Compared to lenograstim, pegfilgrastim was found to be dominant over the 11-day 
regimen and cost-effective over the 6-day regimen (ICER: € 15,546). cOnclusiOns: 
Our findings suggests that pegfilgrastim for the prophylaxis of chemotherapy-
induced FN in breast cancer patients is associated with greater health benefit and 
lower cost over 11-day use of lenograstim, while it is a cost-effective option over 
either the 6-day or the 11-day regimen of biosimilar filgrastim, in Greece.
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Objectives: Hungarian adaptation of global cost-effectiveness models of vismod-
egib vs. standard of care (SOC) in the treatment of locally advanced or symptomatic 
metastatic basal cell carcinoma (laBCC and mBCC). MethOds: Global Markov-
models were developed to compare the cost-effectiveness of vismodegib vs. SOC 
in patients with laBCC or mBCC. The model inputs were based on the pivotal phase 
II clinical study (ERIVANCE). Health state utility values were based on a time trade 
off study. To support the reimbursement dossier submission, the adaptation of the 
global cost-effectiveness models was conducted. The costs and resource use were 
recalculated based on a questionnaire survey with Hungarian health care profes-
sionals. In the model there were two treatment arms, vismodegib and SOC. The 
model had three states, progression-free, progressed and death. For progression-free 
survival (PFS) and overall survival (OS) the results of the phase II clinical trial were 
used in the vismodegib arm of the model. Originally on the SOC arm the model 
calculated with mortality data of the general population, due to lack of relevant data 
on the PFS and OS of patients with advanced BCC. Therefore, a research (Delphi-
panel survey) was conducted to estimate the OS of patients with laBCC and mBCC, 
treated with SOC. Results: According to the Delphi-panel survey the median OS for 
patients with laBCC and mBCC was 48 months and 24 months, respectively, on the 
SOC arm. The average time spent in progression-free health state is longer with vis-
5-year time horizon, PFS data assessed by independent review, drug doses adjusted 
by relative dose intensity reported in COMPARZ trial and a discount rate of 3% for 
costs and outcomes. Results were expressed as € 2014. Deterministic (10-year time 
horizon, discount rates 0 and 5%, PFS assessed by investigator, and plenty-doses) 
and probabilistic sensitivity analyses were conducted to determine the robustness 
of the results. Results: In the base case analysis, pazopanib showed as a dominant 
alternative, yielding more quality of life adjusted years (0.081) and less total costs 
(€ 6,671) vs. sunitinib. Base-case results were robust in the alternative scenarios 
examined via deterministic sensitivity analyses. In the probabilistic sensitivity 
analysis (PSA), a 67% of the simulations were plotted in the dominant quadrant of 
the cost-effectiveness plane. cOnclusiOns: In the light of the present analysis, 
pazopanib should be considered as a dominant alternative vs. sunitinib in the first-
line mRCC treatment from the Spanish National Healthcare perspective.
PCN108
ECoNomiC EvaluatioN of thE usE of GEfitiNiB for thE trEatmENt of 
loCally advaNCEd or mEtastatiC NsClC
Polanco A.C.1, Salazar A.1, Pizarro M.2, Carpio E.1, González L.A.3
1AstraZeneca, Tlalpan, Mexico, 2Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, 
3Health Solutions Consulting, D. F., Mexico
Non-small-cell lung cancer (NSCLC) is the most common type of cancer repre-
senting 18.2% of all cancer deaths around the world and in Mexico the estimated 
mortality rate is 13.4 by 100,000 patients. Objectives: Evaluate gefitinib as first 
and second line treatment of locally advanced or metastatic NSCLC compared to 
available treatment alternatives in Mexico. MethOds: A two-way analysis was per-
formed: (1) For the first-line treatment in patients with Epidermal Growth Factor 
Receptor Inhibition in Mutation-Positive Non–Small-Cell Lung Cancer (EGFR M+ 
NSCLC) a cost-minimization analysis was used comparing gefitinib versus erlotinib 
(Kim ST, 2012), also a Markov model was developed to perform a cost-effectiveness 
analysis evaluating gefitinib versus carboplatin+paclitaxel (Mok TS, 2009), with 
efficacy measure Progression-free survival (PFS); and (2) For patients in a second-
line NSCLC treatment, regardless of EGFR mutation, a cost-minimization analy-
sis was conducted comparing gefitinib versus docetaxel and pemetrexed (Hanna 
N, 2004) (Kim ES, 2008). The costs were obtained from institutional sources. An 
exchange rate of $13.12 MXN per USD was used. Sensitivity analyses were per-
formed in order to test the robustness of the model. Results: For first-line treat-
ment, gefitinib was a cost-saving alternative respect to erlotinib, obtaining a cost 
differential of $9,710 USD in favor of gefitinib. To the same patients gefitinib com-
pared to carboplatin plus paclitaxel generated an additional cost of $2,361 USD 
per patient, with additional PFS of 0.37 years and an ICER of $7,023. For second-
line treatment gefitinib had a lower cost compared to pemetrexed and docetaxel, 
generating a saving per patient of $927 USD and $21,346 USD respectively. Robustness 
of results was confirmed by additional deterministic and probabilistic sensitivity 
analysis. cOnclusiOns: The use of gefitinib for the treatment of locally advanced or 
metastatic NSCLC is a cost-saving alternative compared to erlotinib, pemetrexed and 
docetaxel, and also cost-effective compared to carboplatin plus paclitaxel.
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Objectives: This study aimed to estimate the cost-effectiveness of Ofatumumab 
plus Chlorambucil (OChl) compared with Chlorambucil (Chl) for patients with 
Chronic Lymphocytic Leukemia for whom fludarabine-based therapies are consid-
ered inappropriate, from the perspective of the publicly funded health care system 
in Canada. MethOds: A semi-Markov based decision model was developed with a 
lifetime time horizon. The model comprised two distinct phases. The preprogression 
phase was based on the overall response rates (ORR), progression free survival (PFS) 
and overall survival (OS) observed in the COMPLEMENT-1 trial. The postprogression 
phase was based on Canadian treatment practices, treatment patterns identified 
in clinical guidelines and published literature. The incremental cost per quality-
adjusted life year (QALY) gained was computed using model-estimated first- and 
subsequent-line treatment costs, general disease management costs, and QALYs 
based on health-state preference utility weights. Results: The discounted, lifetime 
health and economic outcomes estimated by the model showed that first-line treat-
ment with OChl in comparison with Chl in the target population led to an increase in 
QALYs (0.41) and an increase in total costs (CAD $27,850), resulting in an incremental 
cost-effectiveness ratio (ICER) of CAD $68,672/QALY gained. Various scenario analyses 
indicated that the cost-effectiveness results were sensitive to the time horizon, the 
method used to assess response, and the extrapolation of OS treatment effect beyond 
the trial period. One way and probabilistic sensitivity analyses aligned with the results 
of the base-case analysis. cOnclusiOns: The base-case results indicate that the 
improved ORR, PFS, and OS for OChl in comparison with Chl translate to improved 
long-term health outcomes. The analysis found that the ICER for OChl versus Chl in 
the target population was CAD $68,672/QALY gained. A variety of sensitivity and sce-
nario analyses confirmed that the model’s cost-effectiveness estimates were robust.
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